within Pharmacolibrary.Drugs.ATC.J;

model J05AP08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.0011833333333333333,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.127,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.067,
    k12             = 236,
    k21             = 236
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AP08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus (HCV) NS5B polymerase. It is an antiviral drug used in combination with other direct-acting antivirals for the treatment of chronic hepatitis C infection. It is approved and widely used as part of combination therapies (e.g., with ledipasvir, velpatasvir, or daclatasvir) and has become a key component in HCV treatment regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Cholongitas, E, &amp; Papatheodoridis, GV (2014). Sofosbuvir: a novel oral agent for chronic hepatitis C. <i>Annals of gastroenterology</i> 27(4) 331–337. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25332066/&quot;>https://pubmed.ncbi.nlm.nih.gov/25332066</a></p></li><li><p>Keating, GM, &amp; Vaidya, A (2014). Sofosbuvir: first global approval. <i>Drugs</i> 74(2) 273–282. DOI:<a href=&quot;https://doi.org/10.1007/s40265-014-0179-7&quot;>10.1007/s40265-014-0179-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24442794/&quot;>https://pubmed.ncbi.nlm.nih.gov/24442794</a></p></li><li><p>Fahmy, SN, et al., &amp; El-Demerdash, E (2024). Effect of carvedilol on pharmacokinetics of sofosbuvir and its metabolite GS-331007: role of P-glycoprotein. <i>The Journal of pharmacy and pharmacology</i> 76(8) 1051–1064. DOI:<a href=&quot;https://doi.org/10.1093/jpp/rgae070&quot;>10.1093/jpp/rgae070</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38850570/&quot;>https://pubmed.ncbi.nlm.nih.gov/38850570</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AP08;
